| Literature DB >> 36249418 |
Beniamino Palmieri1,2, Maria Vadalà1,2.
Abstract
Aim: Several studies emphasized the antiviral properties of many natural compounds enclosed in nutraceuticals formulas and quite effective to prevent the respiratory infections. The rationale of our investigation has been to achieve protection from common cold viruses' infection of the upper airways pooling together and dispensing different active principles on a multistep defense basis. Material and Methods. 30 patients affected by sudden aspecific viral-induced sore throat rhinitis were divided in two groups: (1) the first group included 15 patients which were administered with our spray formula and (2) the second group included 15 patients with the commercial nasal lavage kit. The mucous smear was stained with May Grunwald-Giemsa to exclude eosinophilic infiltrate and confirm the prevalence of granulocytes and lympho-monocytes typical of viral seasonal inflammatory upper airways conditions.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36249418 PMCID: PMC9553441 DOI: 10.1155/2022/2502199
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.493
Common pathogens concerned in respiratory tract infections (bacteria, viruses, and fungi).
| Pathogen | Type gram | Pathology | Ref. |
|---|---|---|---|
|
| + | Bacterial pneumonia | [ |
|
| − | Pneumonia, sinusitis | [ |
|
| Obligate intracellular bacterium | Atypical pneumonia | [ |
|
| + | Sinusitis, pneumonia | [ |
|
| − | Sinusitis, pneumonia | [ |
|
| − | Cough with sputum, bronchiolitis | [ |
|
| − | Bronchitis, sinusitis, and bronchopneumonia | [ |
| Rhinoviruses | Enterovirus | Common cold and sinusitis | [ |
| Coronaviruses | Coronavirinae | Pneumonia | [ |
| Respiratory syncytial virus | Pneumovirus | Bronchiolitis | [ |
| Adenovirus | Adenoviridae | Pneumonia and tonsillitis, | [ |
| Herpes simplex virus | Respirovirus | Pneumonia | [ |
|
|
| Pneumonia | [ |
|
|
| Pneumonia | [ |
|
|
| Pneumonia | [ |
|
| Pneumonia | [ |
Estimated annual proportion of clinical case based on virus' type.
| Virus's type | Estimated annual proportion of cases |
|---|---|
| Rhinovirus | 30–50% |
| Coronavirus | 10–15% |
| Influenza virus | 5–15% |
| Respiratory syncytial virus | 5% |
| Parainfluenza virus | 5% |
| Adenovirus | <5% |
| Enterovirus | <5% |
| Metapneumovirus | Unknown |
| Unknown | 20–30% |
Characteristic of patients.
| First group | Second group | |||||
|---|---|---|---|---|---|---|
| Patient ID | Age (years) | Sex | Patient ID | Age (years) | Sex | |
| #1 | P.E. | 76 | M | D.B. | 36 | F |
| #2 | M.G. | 64 | M | M.C. | 73 | M |
| #3 | F.W. | 55 | F | A.C. | 62 | M |
| #4 | V.F. | 61 | F | S.E. | 76 | M |
| #5 | B.C. | 66 | M | A.U. | 56 | F |
| #6 | S.V. | 78 | F | B.A. | 59 | M |
| #7 | C.A. | 56 | M | F.M. | 68 | M |
| #8 | P.M. | 51 | F | M.C. | 49 | M |
| #9 | C.M. | 62 | M | S.E. | 61 | M |
| #10 | R.S. | 38 | M | V.K. | 76 | M |
| #11 | B.M. | 47 | M | A.G. | 64 | F |
| #12 | L.A. | 61 | F | L.P. | 45 | F |
| #13 | E.R. | 54 | F | A.T. | 51 | F |
| #14 | M.B. | 66 | F | D.E. | 38 | F |
| #15 | A.A. | 36 | M | I.F. | 53 | F |
Description of symptoms in the first group (our spray) after treatment.
| First group | Symptoms posttreatment | ||||||
|---|---|---|---|---|---|---|---|
| Nasal obstruction | Blow the nose | Sneezing | Mucous discharge | Pharyngeal soreness | Throat scraping | Laryngeal cough | |
| P.E. | Rare | Intermittent | Absent | Absent | Absent | Rare | Absent |
| M.G. | Rare | Absent | Intermittent | Absent | Persistent | Intermittent | Absent |
| F.W. | Absent | Absent | Rare | Intermittent | Intermittent | Rare | Absent |
| V.F. | Absent | Absent | Rare | Persistent | Rare | Rare | Rare |
| B.C. | Rare | Rare | Absent | Absent | Intermittent | Absent | Intermittent |
| S.V. | Rare | Absent | Intermittent | Absent | Rare | Rare | |
| C.A. | Absent | Intermittent | Absent | Persistent | Rare | Rare | Absent |
| P.M. | Absent | Rare | Rare | Intermittent | Rare | Absent | Intermittent |
| C.M. | Rare | Intermittent | Absent | Intermittent | Absent | Rare | Rare |
| R.S. | Absent | Absent | Rare | Intermittent | Persistent | Intermittent | Persistent |
| B.M. | Rare | Absent | Absent | Absent | Absent | Rare | Intermittent |
| L.A. | Intermittent | Rare | Intermittent | Absent | Rare | Rare | Absent |
| E.R. | Rare | Absent | Absent | Rare | Rare | Absent | Absent |
| M.B. | Absent | Intermittent | Rare | Intermittent | Intermittent | Absent | Absent |
| A.A. | Intermittent | Rare | Rare | Rare | Absent | Intermittent | Rare |
Figure 1Graphical representation of symptoms in first and second group after treatment. There were significant differences. ∗∗∗∗P < 0.0001 first- vs. second group.
Description of symptoms in the second group (commercial spray) after treatment.
| Second group | Symptoms post-treatment | ||||||
|---|---|---|---|---|---|---|---|
| Nasal obstruction | Blow the nose | Sneezing | Mucous discharge | Pharyngeal soreness | Throat scraping | Laryngeal cough | |
| D.B. | Persistent | Intermittent | Absent | Absent | Persistent | Rare | Persistent |
| M.C. | Rare | Absent | Intermittent | Absent | Persistent | Intermittent | Absent |
| A.C. | Rare | Intermittent | Persistent | Rare | Intermittent | Rare | Absent |
| S.E. | Intermittent | Absent | Rare | Persistent | Persistent | Intermittent | Rare |
| A.U. | Absent | Rare | Persistent | Absent | Intermittent | Persistent | Intermittent |
| B.A. | Intermittent | Persistent | Intermittent | Absent | Intermittent | Rare | Persistent |
| F.M. | Persistent | Intermittent | Absent | Persistent | Rare | Rare | Absent |
| M.C. | Absent | Persistent | Rare | Intermittent | Rare | Persistent | Intermittent |
| S.E. | Persistent | Intermittent | Absent | Absent | Persistent | Rare | Persistent |
| V.K. | Absent | Absent | Intermittent | Absent | Persistent | Intermittent | Absent |
| A.G. | Persistent | Intermittent | Persistent | Rare | Intermittent | Rare | Absent |
| L.P. | Intermittent | Absent | Rare | Persistent | Persistent | Intermittent | Rare |
| A.T. | Rare | Rare | Persistent | Absent | Intermittent | Rare | Intermittent |
| D.E. | Intermittent | Persistent | Intermittent | Persistent | Intermittent | Rare | Persistent |
| I.F. | Persistent | Intermittent | Absent | Persistent | Rare | Rare | Absent |
Case report of 10 healthy voluntaries, carriers of SARS-CoV-2, treated with our spray.
| Case report | Sex | Age | 2 consecutive swab before | Day 3 | Day 5 | |
|---|---|---|---|---|---|---|
| Patient ID | Swab1 | Swab2 | Swab3 | Swab4 | ||
| D.B. | F | 36 | + + | + + | Negative | Negative |
| M.C. | M | 73 | + + | + + | Negative | Negative |
| A.C. | M | 62 | + + | + + | Negative | Negative |
| S.E. | M | 76 | + + | + + | Negative | Negative |
| A.U. | F | 56 | + + | + + | Negative | Negative |
| B.A. | M | 59 | + + | + + | + + | Negative |
| F.M. | M | 68 | + + | + + | + + | Negative |
| M.C. | M | 49 | + + | + + | Negative | Negative |
| S.E. | M | 61 | + + | + + | Negative | Negative |
| V.K. | M | 76 | + + | + + | + + | Negative |
| Positivity index | 10/10 | 10/10 | 3/10 | 0/10 | ||